1389 related articles for article (PubMed ID: 25259745)
1. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Muntner P; Davis BR; Cushman WC; Bangalore S; Calhoun DA; Pressel SL; Black HR; Kostis JB; Probstfield JL; Whelton PK; Rahman M;
Hypertension; 2014 Nov; 64(5):1012-21. PubMed ID: 25259745
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Apparent Therapy-Resistant Hypertension and Its Effect on Outcome in Patients With Chronic Kidney Disease.
de Beus E; Bots ML; van Zuilen AD; Wetzels JF; Blankestijn PJ;
Hypertension; 2015 Nov; 66(5):998-1005. PubMed ID: 26351024
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study.
Thomas G; Xie D; Chen HY; Anderson AH; Appel LJ; Bodana S; Brecklin CS; Drawz P; Flack JM; Miller ER; Steigerwalt SP; Townsend RR; Weir MR; Wright JT; Rahman M;
Hypertension; 2016 Feb; 67(2):387-96. PubMed ID: 26711738
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Health and Transition From Controlled Blood Pressure to Apparent Treatment Resistant Hypertension: The Jackson Heart Study and the REGARDS Study.
Akinyelure OP; Sakhuja S; Colvin CL; Clark D; Jaeger BC; Hardy ST; Howard G; Cohen LP; Irvin MR; Tanner R; Carey RM; Muntner P
Hypertension; 2020 Dec; 76(6):1953-1961. PubMed ID: 33131312
[TBL] [Abstract][Full Text] [Related]
5. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
[TBL] [Abstract][Full Text] [Related]
6. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality.
Irvin MR; Booth JN; Shimbo D; Lackland DT; Oparil S; Howard G; Safford MM; Muntner P; Calhoun DA
J Am Soc Hypertens; 2014 Jun; 8(6):405-13. PubMed ID: 24952653
[TBL] [Abstract][Full Text] [Related]
7. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
[TBL] [Abstract][Full Text] [Related]
8. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
[TBL] [Abstract][Full Text] [Related]
9. The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Kronish IM; Lynch AI; Oparil S; Whittle J; Davis BR; Simpson LM; Krousel-Wood M; Cushman WC; Chang TI; Muntner P
Hypertension; 2016 Jul; 68(1):39-45. PubMed ID: 27217410
[TBL] [Abstract][Full Text] [Related]
10. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
Oparil S; Bakir SE
Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
[TBL] [Abstract][Full Text] [Related]
11. Prediction of cardiovascular and renal risk among patients with apparent treatment-resistant hypertension in the United States using machine learning methods.
Bakris G; Lin PP; Xu C; Chen C; Ashton V; Singhal M
J Clin Hypertens (Greenwich); 2024 May; 26(5):500-513. PubMed ID: 38523465
[TBL] [Abstract][Full Text] [Related]
12. Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.
Bangalore S; Davis BR; Cushman WC; Pressel SL; Muntner PM; Calhoun DA; Kostis JB; Whelton PK; Probstfield JL; Rahman M; Black HR;
Am J Med; 2017 Apr; 130(4):439-448.e9. PubMed ID: 27984005
[TBL] [Abstract][Full Text] [Related]
13. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Haywood LJ; Ford CE; Crow RS; Davis BR; Massie BM; Einhorn PT; Williard A;
J Am Coll Cardiol; 2009 Nov; 54(22):2023-31. PubMed ID: 19926008
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease.
Bangalore S; Fayyad R; Laskey R; Demicco DA; Deedwania P; Kostis JB; Messerli FH;
Am J Med; 2014 Jan; 127(1):71-81.e1. PubMed ID: 24210549
[TBL] [Abstract][Full Text] [Related]
15. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group
Hypertension; 2003 Sep; 42(3):239-46. PubMed ID: 12925554
[TBL] [Abstract][Full Text] [Related]
16. Underutilization of Treatment for Black Adults With Apparent Treatment-Resistant Hypertension: JHS and the REGARDS Study.
Langford AT; Akinyelure OP; Moore TL; Howard G; Min YI; Hillegass WB; Bress AP; Tajeu GS; Butler M; Jaeger BC; Yano Y; Shimbo D; Ogedegbe G; Calhoun D; Booth JN; Muntner P
Hypertension; 2020 Nov; 76(5):1600-1607. PubMed ID: 32924633
[TBL] [Abstract][Full Text] [Related]
17. Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus.
Bakris G; Chen C; Campbell AK; Ashton V; Haskell L; Singhal M
J Clin Hypertens (Greenwich); 2023 Aug; 25(8):737-747. PubMed ID: 37461262
[TBL] [Abstract][Full Text] [Related]
18. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Black HR; Davis B; Barzilay J; Nwachuku C; Baimbridge C; Marginean H; Wright JT; Basile J; Wong ND; Whelton P; Dart RA; Thadani U;
Diabetes Care; 2008 Feb; 31(2):353-60. PubMed ID: 18000186
[TBL] [Abstract][Full Text] [Related]
19. [Clinical study of the month. Which initial antihypertensive? Results from the ALLHAT trial].
Scheen AJ; Krzesinski JM
Rev Med Liege; 2003 Jan; 58(1):47-52. PubMed ID: 12647599
[TBL] [Abstract][Full Text] [Related]
20. Resistant Hypertension, Time-Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus.
Viazzi F; Piscitelli P; Ceriello A; Fioretto P; Giorda C; Guida P; Russo G; De Cosmo S; Pontremoli R;
J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28939716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
